A special inspection of medical corruption has come.

Medical Network August 10, recently, a judgment of the Chinese referee instrument network shows that the former director of a three-a hospital was sentenced for bribery. according to the judgment of
, Wang Jianmin, the former director of a hospital in Sichuan Province, used his position to obtain benefits for others in the procurement of drugs and equipment between 2005 and 2019, receiving property of 2.417204 million yuan, was sentenced to four years' imprisonment and a fine of 400,000 yuan.
at the same time, its illegal income of 620,000 yuan to the State Treasury (paid), its houses and parking, 116,000 U.S. dollars (equivalent to 821.1524 million yuan) to be recovered, turned over to the state treasury.
Seiberlan according to public information combing found that only in the first half of 2020, there have been a number of hospital directors, department heads have fallen, most of the reasons for investigation around drugs, medical supplies and other fields to receive kickbacks or use authority to intervene in infrastructure projects.
in fact, in recent years from the grass-roots community to the hospital, the director, section director because of bribery is not uncommon.
according to incomplete statistics, there will be more than 300 hospital directors in 2019, including 18 in The Third A hospital. Before the
, there are prosecution officers publicly said that medical corruption involved in many departments, personnel, up to the director, the president, down to the chief of the pharmaceutical department, finance section chief, procurement officers, medical personnel, often investigate and deal with a number of cases, the seizure of one person led several or even dozens of people.
So we can also see that in recent years, medical anti-corruption work, medical personnel are the focus of inspection.
on the issue of medical corruption, the Central Commission for Discipline Inspection of the State Supervision and Supervision Commission in the State Health and Health Commission discipline inspection and supervision team responsible for the relevant person has said that will increase the pressure transmission, in accordance with the "who is in charge, who is responsible" and "the management industry must manage the wind" requirements, around the medical and health field outstanding issues, in-depth special rectification.
marketing costs remain high, pharmaceutical companies were named recently, a number of listed pharmaceutical companies received the 2019 annual report of the Shenzhen Stock Exchange inquiry letter, asked to explain the proportion of academic promotion fees to sales costs, whether the sales fee rate is at a reasonable level in the industry, and whether there is commercial bribery or commercial bribery to facilitate the situation.
according to The Net, of the 306 pharmaceutical-related listed enterprises, 39 have revenues exceeding 10 billion in 2019, of which 8 have more than 5 billion yuan in sales costs, and 33 pharmaceutical companies will have sales expenses of more than 50% in 2019.
overall figures, this growth rate is lower than in the past, but there is still a problem with high cost of drug sales. What exactly does
cost of selling pharmaceutical companies? As the Accounting Standards for Enterprises do not specify this, the sales costs of each listed pharmaceutical company are divided into different accounts.
common subjects are employee compensation, market costs, conference fees, business (entertainment) fees, travel expenses, advertising (propaganda) fees and transportation costs, enterprises can adjust the subject according to the actual situation, some enterprises for the sake of sales channels, as well as rental fees, depreciation fees and other sales of construction equipment costs.
from the listed pharmaceutical companies sales costs, its list of more names, including sales staff compensation, daily administrative costs, marketing and academic promotion.
in addition, prescription drug companies to market costs, conference fees, consulting fees are the main items of sales costs.
an ombudsman of the Ministry of Finance said that although a large number of sales costs are actually occurring, but there is a large part of the only withdrawal in the name of sales costs to transfer funds to third-party intermediary companies, such companies are mostly in the face of consulting services companies, no actual business, has become a gray area for enterprises to withdraw funds.
at present, the sales and sales expenses of pharmaceutical companies have become the main cost component of the "ex-factory price" of drugs, and in the drug supply chain, the circulation link accounts for the majority of the drug operating costs.
in some cases, sales costs eat up the original profits of pharmaceutical companies, even more than their cost expenditure, forming a pathological growth mechanism.
, therefore, the cost of sales of pharmaceutical companies is also the focus of the relevant departments in recent years.
last June, the Ministry of Finance and the Health Insurance Administration jointly checked the financial problems of 77 pharmaceutical companies, focusing on sales costs.
in accordance with the requirements of the Ministry of Finance, the contents of the inspection include the pharmaceutical companies to comply with accounting laws and regulations, financial accounting systems, internal control norms and other circumstances, but also the pharmaceutical enterprises expenses, costs, income authenticity.
especially the authenticity of sales expenses, cost authenticity, the authenticity of revenue, sales rebate rebates and other issues.
under the policy background of two-vote system and medical insurance control fee, the relevant departments continue to investigate the sales costs of pharmaceutical companies.
strict lying checks of kickbacks, inspection and covert visit group set off recently, the State Health and Health Commission issued "on the issuance of 2020 medical industry style construction work special action program notice" (State Health Office medical letter (2020) No. 592).
According to the notice, the special rectification period is from July to December 2020 and is divided into three stages: the education and self-examination phase (July 2020): health administration departments at all levels and medical institutions organize working meetings to mobilize and deploy widely.
focused on publicity and rectification (August-November 2020): special inspectionvisits continue to be carried out in various places.
Assessment and Summary Phase (December 2020): Summary and evaluation of the special rectification work in the region.
from the timing point of view, has now entered August, I believe that some areas of the special inspection and covert visit team should have started.
the National Health and Care Commission clearly, to carry out a special crackdown on the collection of kickbacks by medical institutions, and to investigate and punish medical institutions and their practitioners to use their practice to seek improper benefits and collect kickbacks.
, for medical institutions, focus on the following six kinds of behavior: 1, medical institutions to accept pharmaceutical products such as drugs, medical equipment, medical hygiene materials production, business enterprises or distribution personnel in various names, forms of rebate behavior; Cheng's behavior; 4, medical institutions and their practitioners in violation of regulations to publish medical advertisements, participate in pharmaceutical products, food, health care products and other commodity marketing activities; 5, medical personnel use any means and means for commercial purposes of the physician's personal and clinical departments of the consumption of drugs, medical supplies information, to facilitate the statistics of pharmaceutical marketers; 6, medical personnel in violation of the provisions of private procurement, sale, use of drugs, medical equipment, medical health materials and other pharmaceutical products.
for pharmaceutical enterprises, serious investigation and punishment of pharmaceutical products production, business distribution personnel in medical institutions in violation of the marketing behavior.
focus on the inspection of medical institutions outpatient, inpatient, pharmacy and other areas of pharmaceutical products production, business enterprises or distribution personnel illegally sell drugs, medical equipment to medical personnel, business negotiations.
the medical anti-corruption will continue to escalate as the group departs.
once the doctor, the dean is investigated, the drug companies involved can be safe? Obviously not.
in this round of inspection and covert visits, the pharmaceutical companies should also self-check in advance.
compliance is the hard truth for long-term development.
.